DalsnaFinance

Tango Therapeutics Inc $TNGX

Health Care

Russell 2000 Massachusetts
Create a scorecard
$27.93
+0.95 (+3.52%)
As of Oct 22, 2026, 9:34 PM EDT · cached
Price history
Loading chart…
Today's analyst average Analyst average over timeIndividual analyst targets Analyst history starts Oct 13, 2026, the first target we tracked for TNGX.

Tango Therapeutics Inc (TNGX) is trading up at $27.93 (+3.52%), as of the latest quote. It is a Russell 2000 constituent in the Health Care sector.

Analyst price targets on TNGX

One firm's current price target on Tango Therapeutics Inc: $48 — 72% above the current $27.9. Each is tracked to its date and scored the same way a member's call is.

Targets published by research firms, extracted from the news, checked against independent reporting, and linked to their source. Where a firm did not state a horizon the target is tracked as 12 months, the industry convention; the rows where the firm set its own horizon are marked. Reported here as facts about what was published — not recommendations from Dalsna Finance, and no firm listed is affiliated with this site.

Tango Therapeutics Inc revenue & net income history (FY2020–FY2025)

RevenueNet incomeNet margin (right axis, %)
$62.4M−$34.0M−$130.3MFY2020 revenue: $7.66MFY2020 net income: −$52.0M · Net margin −678.8%'20FY2021 revenue: $37.0MFY2021 net income: −$58.2M · Net margin −157.2%'21FY2022 revenue: $24.9MFY2022 net income: −$108.2M · Net margin −435.1%'22FY2023 revenue: $36.5MFY2023 net income: −$101.7M · Net margin −278.5%'23FY2024 revenue: $42.1MFY2024 net income: −$130.3M · Net margin −309.7%'24FY2025 revenue: $62.4MFY2025 net income: −$101.6M · Net margin −162.9%'25−100%−50%0%FY2020 net margin: −678.8% (off the scale, which stops at −100.0%)FY2021 net margin: −157.2% (off the scale, which stops at −100.0%)FY2022 net margin: −435.1% (off the scale, which stops at −100.0%)FY2023 net margin: −278.5% (off the scale, which stops at −100.0%)FY2024 net margin: −309.7% (off the scale, which stops at −100.0%)FY2025 net margin: −162.9% (off the scale, which stops at −100.0%)
Tango Therapeutics Inc annual financial statements
FY2020Dec 2020FY2021Dec 2021FY2022Dec 2022FY2023Dec 2023FY2024Dec 2024FY2025Dec 2025
Income statement
Revenue$7.66M$37.0M$24.9M$36.5M$42.1M$62.4M
Growth (year over year)—+383.8%−32.9%+46.9%+15.2%+48.3%
Operating income−$52.2M−$58.2M−$111.1M−$114.2M−$145.6M−$111.3M
Operating margin−681.8%−157.1%−446.8%−312.6%−346.1%−178.4%
Net income−$52.0M−$58.2M−$108.2M−$101.7M−$130.3M−$101.6M
Net margin−678.8%−157.2%−435.1%−278.5%−309.7%−162.9%
EPS (diluted)−$1.63−$0.94−$1.23−$1.08−$1.19−$0.87
Balance sheet
Cash and equivalents$28.4M$142.7M$60.0M$66.4M$69.5M$112.3M
Total assets$207.3M$500.2M$436.5M$402.6M$316.5M$398.7M
Total liabilities$168.7M$155.4M$187.0M$149.5M$117.0M$52.5M
Shareholders' equity$38.6M$344.7M$249.5M$253.1M$199.5M$346.2M
Cash flow
Operating cash flow$70.1M−$59.5M−$109.1M−$118.0M−$131.5M−$138.9M
Capital expenditure$1.11M$1.84M$7.69M$1.53M$754.0K$1.05M
Free cash flow$69.0M−$61.4M−$116.8M−$119.5M−$132.3M−$139.9M

From Tango Therapeutics Inc's 10-K and 10-Q filings with the SEC; its fiscal year ends in December. Each period shows the latest figure the company has reported for it, including restatements. Net margin is our own calculation from those reported figures (net income ÷ revenue); it is left blank where revenue is zero or missing. † Quarter derived from the company's year-to-date or full-year totals. Filings on SEC EDGAR →

About Tango Therapeutics Inc

Headquarters
Boston, Massachusetts From SEC filings, Oct 2026

Recent News (3)

More Health Care stocks

Browse all companies →